<div id="readability-page-1"><div><p>Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday.</p><p>The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. </p><p>Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders, including depression, anxiety, and other central nervous system conditions. The company uses its proprietary Glyph platform, a lymphatic-targeting prodrug technology designed to improve oral bioavailability and reduce first-pass metabolism, to reformulate clinically validated mechanisms into differentiated product candidates. Its lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with additional preclinical candidates targeting depressive and related CNS disorders.</p><p>Seaport Therapeutics was founded in 2024. It plans to list on the Nasdaq under the symbol SPTX. Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel are the joint bookrunners on the deal. It is expected to price the week of April 27, 2026.</p></div></div>

SEEL

ARKG

LABU

<p>Seaport Therapeutics, a Boston-based biotech firm focused on neuropsychiatric therapies, has announced terms for its $201 million IPO, planning to offer 11.8 million shares priced between $16 and $18. The company, founded in 2024, is developing oral therapies for conditions like depression and anxiety using its proprietary Glyph platform. Its lead programs include GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder. Seaport plans to list on Nasdaq under the symbol SPTX, with pricing expected the week of April 27, 2026.</p>

RenaissanceCapital

Seelos Therapeutics

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

VG Health

SPDR S&P Biotech

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Nasdaq

Goldman Sachs

JPMorgan Chase

Citigroup

Stifel Financial

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week